The clinical experience of antisense therapy to ICAM-1 in Crohn's disease

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 3, 1999, Pages 332-335

  Yacyshyn, Bruce ^a   Bowen Yacyshyn, M B ^a   Shanahan, William ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN;

ADULT; AGED; ANIMAL TISSUE; CLINICAL TRIAL; CROHN DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECTAL DRUG ADMINISTRATION; REMISSION; REVIEW; TOPICAL DRUG ADMINISTRATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; AUTOIMMUNE DISEASES; BETA 2-MICROGLOBULIN; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COLITIS; CROHN DISEASE; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; GENE THERAPY; HLA-B27 ANTIGEN; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MICE; MODELS, ANIMAL; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGORIBONUCLEOTIDES, ANTISENSE; PILOT PROJECTS; RATS; REMISSION INDUCTION; RNA, MESSENGER; SAFETY; THIONUCLEOTIDES; TREATMENT OUTCOME;

ANIMALIA;

EID: 0032989151     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (9)

1. Bennett CF, Condon TP, Grimm S, Chan H, Chiang M-Y: Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol (1994) 152:3530-3540.
2. Chiang M-Y, Chan H, Zounes MA, Freire SM, Lima WF, Bennett CF: Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem (1991) 266:18162-18171.
3. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR Jr: A placebo-controlled trial of an ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology (1998) 114:1133-1142. •• A description of the first clinical use of systemically-administered antisense in a human disease application.
4. Bennett CF, Kombrust D, Henry S, Stecker K, Howard R, Cooper S, Dutson S, Hall W, Jacoby HI: An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharmacol Exp Ther (1997) 280:988-1000. • Results showed both a preventative and ameliorative effect of antisense administration.
5. Neurath MF, Pettersson S, Meyer zum Büschenfelde KH, Strober W: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med (1996) 2:998-1004. • This work showed effect of topical antisense to NFκB in an experimental colitis model.
6. Akira S, Kishimoto T: NF-IL6 and NF-κB in cytokine gene regulation. Adv Immunol (1997) 65:1-46. • Review of NFκB in the regulation of inflammation.
7. Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE: Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol (1993) 150:4168-4178. • These results showed the role of the copy number of HLA-B27 in inflammatory disease.
8. Glover JM, Leeds JM, Mant TGK, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA, Shanahan WR Jr: Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther (1997) 282:1173-1180. • Phase I study of ISIS-2302.
9. Hokari R, Miura S, Fujimoro H, Nagata H, Sekizuka E, Tsuzuki Y, Kurose I, Serizawa H, Suematsu M, Yagita H, Granger DN, Ishii H: Lymphocyte outflux to intestinal microlymphatics is an intercellular adhesion molecule-1 dependent process in Peyer's patches. Gastroenterology (1997) 112(4):A369.